 KemPharm Inc NASDAQ: KMPH has amended the collaboration and license agreement with Gurnet Point Capital GPC, a private investment firm. The agreement provides for an exclusive worldwide license to develop, manufacture, and commercialize KemPharms product candidates containing serdexmethylphenidate SDX and d-methylphenidate d-MPH. 